Although some studies have examined the relationship between residual mutated IDH1 in CR and subsequent clinical outcomes [21, 26, 27], definitive nation-level standardized evidence to inform decision making for the clinical utility of IDH1 as a target for AML MRD testing was not previously available. The gene discussed is IDH1; the disease is acute myeloid leukemia.